For research use only. Not for therapeutic Use.
JNJ-28583113（Cat No.:I041192）is an investigational small molecule being developed by Johnson & Johnson for the treatment of various cancers. It is a potent inhibitor of a specific protein kinase involved in regulating cell proliferation, survival, and tumor progression. By blocking this kinase, JNJ-28583113 aims to halt cancer cell growth, reduce tumor size, and enhance the effectiveness of other cancer therapies. Early preclinical studies have shown promising results, and clinical trials are currently underway to assess its safety, efficacy, and potential as a targeted treatment for solid tumors and hematologic cancers.
| CAS Number | 2765255-93-2 |
| Synonyms | ethyl 2-[3-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]acetate |
| Molecular Formula | C19H21F3N2O2 |
| Purity | ≥95% |
| IUPAC Name | ethyl 2-[3-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]acetate |
| InChI | InChI=1S/C19H21F3N2O2/c1-2-26-17(25)12-24-16-7-5-3-4-6-15(16)18(23-24)13-8-10-14(11-9-13)19(20,21)22/h8-11H,2-7,12H2,1H3 |
| InChIKey | WOERTJPEDOUEDS-UHFFFAOYSA-N |
| SMILES | CCOC(=O)CN1C2=C(CCCCC2)C(=N1)C3=CC=C(C=C3)C(F)(F)F |
